AtaiBeckley, Inc. (ATAI) stock surged nearly 60% overnight late Wednesday following reports that Eli Lilly is in takeover talks with the psychedelic medicine company. The surge came after Magnus Sigurdsson, co-founder of Systematic Ventures and partner at Iron Pine Ventures, estimated a likely acquisition price of $9 to $11 per share, with the top end representing a 105% premium from the last close. The potential acquisition would expand Lilly's neuroscience portfolio and mark a major Big Pharma move into psychedelic medicine, with Lilly reportedly negotiating at a premium to AtaiBeckley's $2 billion market value.
Venture Capitalist Estimates $9 to $11 Per Share Acquisition Price
Magnus Sigurdsson said on X that the talks appear to be the culmination of a structured banking process that AtaiBeckley began around its lead drug, BPL-003, in March. He stated that Eli Lilly appears to have decided that buying the entire company was preferable to licensing or purchasing only the drug. Sigurdsson estimated a likely takeover price of $9 to $11 per share. He added that a rival bidder is "unlikely" given the formal sale process, though a competing offer remains the key source of upside for investors. ATAI stock is now up 4% for the week.
BPL-003 Receives FDA Breakthrough Therapy Designation
AtaiBeckley's lead drug, BPL-003, is a fast-acting nasal treatment for treatment-resistant depression that has received FDA Breakthrough Therapy designation. Mid-stage studies showed improvement in depressive symptoms within two days after a single dose, with benefits lasting up to eight weeks. Speaking at the HCW Neuro Perspectives Conference last month, CEO Srinivas Rao said BPL-003 was designed around a two-hour treatment window similar to Johnson & Johnson's Spravato, with psychedelic effects largely resolving within 90 minutes. The company has begun Phase 3 trials and said the FDA is comfortable with eligible patients being discharged after 2 hours.
FDA Issues Final Guidance for Psychedelic Drug Trials
The takeover speculation follows the FDA's final guidance for psychedelic drug trials, which sets expectations around study design, safety monitoring, abuse potential and durability of treatment response. The FDA acknowledged that psychedelic trials face unusual challenges, particularly "functional unblinding," as patients and clinicians can often tell whether an active drug was administered. The agency recommended evaluating treatment effects at 12 weeks, monitoring patients longer term, and documenting expected effects such as hallucinations and altered cognition as adverse events.
Retail Sentiment Reaches Extremely Bullish Levels
On Stocktwits, retail sentiment for ATAI was "extremely bullish" amid "extremely high" message volume. One user said, "Angermayer (founder) is not out here just trying to make a deal, he wants to make a Statement! He knows he's sitting on a revolutionary product / treatment that is in demand Worldwide. This deal should put ATAI on the map across the Globe." Another user said, "$ATAI = you know its all those TD Cowen, Jefferies and JP Morgan boys running to buy it up as soon as they made the deal today!!" ATAI stock has more than doubled over the past year.
FAQ
What caused ATAI stock to surge nearly 60% overnight late Wednesday?
ATAI stock surged nearly 60% overnight late Wednesday following reports that Eli Lilly is in takeover talks with AtaiBeckley, Inc. Magnus Sigurdsson estimated a likely acquisition price of $9 to $11 per share, with the top end representing a 105% premium from the last close.
What is BPL-003 and what results did it show in mid-stage studies?
BPL-003 is a fast-acting nasal treatment for treatment-resistant depression that has received FDA Breakthrough Therapy designation. Mid-stage studies showed improvement in depressive symptoms within two days after a single dose, with benefits lasting up to eight weeks. The treatment is designed around a two-hour treatment window with psychedelic effects largely resolving within 90 minutes.
